The Dawn of RAS Inhibition in Pancreatic Cancer

Pancreatic cancer remains a deadly disease, and the RAS mutations that drive more than 90% of cases have been, until now, an “undruggable” target. Daraxonrasib, a multiselective RAS inhibitor, was evaluated in an industry-sponsored phase 1–2 study with safety as the primary objective. A total of 168 patients (median age, 65) with advanced RAS-mutated pancreatic adenocarcinoma and a median of two prior systemic therapies received daraxonrasib at a range of doses (83 at the recommended phase 3 dose, 300 mg daily). Approximately 40% and 30% had KRAS G12D and G12V mutations, respectively.